July 28, 2020 |
Brazilian pharmaceutical company Hypera Pharma confirmed Monday that it hired BR Partners to arrange a possible sale of the Xantinon brand to keep antitrust authorities at bay after it closes an $825 million acquisition with Japan's Takeda Pharmaceutical Company.
Local financial newspaper Valor Econômico reported on Friday that Hypera could earn up to BRL250 million ($48.6 million) from the sale Xantinon. The São Paulo-based drugmaker said in a securities filing on Monday that it had not settled
Brazilian drugmaker confirms it could offload the brand once it closes a $825 mln deal with Takeda